Omega Therapeutics, Inc. (NASDAQ: OMGA) was downgraded by analysts at Raymond James from an "outperform" rating to a "market perform" rating.
Omega Therapeutics, Inc. (NASDAQ: OMGA) had its price target lowered by analysts at Piper Sandler from $9.00 to $4.00. They now have an "overweight" rating on the stock.
Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results
Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings